Statin therapy and myocardial no-reflow

British Journal of Pharmacology

Volumn 149, Issue 3, 2006, Pages 229-231

  Calvert, J W ^a   Lefer, D J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary blood flow; Endothelial nitric oxide synthase; Mitochondrial K ATP channels; Nitric oxide

Indexed keywords

CLAMIKALANT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE DONOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SIMVASTATIN;

CELL INTERACTION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DRUG MECHANISM; ENZYME ACTIVITY; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEADY STATE; THROMBOCYTE ADHESION; UPREGULATION;

ANIMALS; CORONARY CIRCULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; NITRIC OXIDE; POTASSIUM CHANNELS; SIMVASTATIN;

EID: 33749009307     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706863     Document Type: Review

References (16)

1. Alfayoumi F, Srinivasan V, Geller M, Gradman A (2005). The no-reflow phenomenon: epidemiology, pathophysiology, and therapeutic approach. Rev Cardiovasc Med 6: 72-83.
2. Dawn B, Bolli R (2002). Role of nitric oxide in myocardial preconditioning. Ann NY Acad Sci 962: 18-41.
3. Folkeringa RJ, Van Kraaij DJ, Tieleman RG, Nieman FH, Pinto YM, Crijns HJ (2006). Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 12: 134-138.
4. ATP channel as a receptor for potassium channel openers. J Biol Chem 271: 8796-8799.
5. Hanley PJ, Daut J (2005). K(ATP) channels and preconditioning: a re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J Mol Cell Cardiol 39: 17-50.
6. Honda HM, Korge P, Weiss JN (2005). Mitochondria and ischemia/reperfusion injury. Ann NY Acad Sci 1047: 248-258.
7. Jones SP, Gibson MF, Rimmer III DM, Gibson TM, Sharp BR, Lefer DJ (2002). Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40: 1172-1178.
8. Jones SP, Teshima Y, Akao M, Marban E (2003). Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 93: 697-699.
9. Jones SP, Trocha SD, Lefer DJ (2001). Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol 21: 2059-2064.
10. Laufs U, Fata VL, Liao JK (1997). Inhibition of 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272: 31725-31729.
11. Laufs U, La Fata V, Plutzky J, Liao JK (1998). Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135.
12. Lefer DJ (2002). Statins as potent antiinflammatory drugs. Circulation 106: 2041-2042.
13. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR et al. (2001). HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 15: 1454-1456.
14. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer III DM, Trocha SD et al. (2001). Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103: 2598-2603.
15. Yamakuchi M, Greer JJ, Cameron SJ, Matsushita K, Morrell CN, Talbot-Fox K et al. (2005). HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 96: 1185-1192.
16. ATP channel. Br J Pharmacol 149: 243-249 (this issue).